Business
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) are dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. STS101 is the only product to combine Satsuma's proprietary SMART™ (Simple MucoAdhesive Release Technology) with an easy-to-use, easy-to carry nasal delivery device.
About this update from Shin Nippon Biomedical Laboratories, Ltd.
[{"type":"text","content":"Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.","length":141,"tagName":"p"},{"type":"text","content":"Exploratory Efficacy Endpoints showed that STS101 provided rapid freedom from pain, from most bothersome symptoms at 2 hours and sustained treatment benefits over 48 hours after dosing.","length":185,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Nov. 5, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) are dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. STS101 is the only product to combine Satsuma's proprietary SMART™ (Simple MucoAdhesive Release Technology) with an easy-to-use, easy-to carry nasal delivery device.","length":484,"tagName":"p"},{"type":"image","alt":"Satsuma Pharmaceuticals (PRNewsfoto/Satsuma Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Satsuma Pharmaceuticals (PRNewsfoto/Satsuma Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":134,"url":"https://media.zenfs.com/en/prnewswire.com/ed276b4d8c5d5ff23262200455ca2c21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2PhjRVul25B4XKRuPr5bhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ed276b4d8c5d5ff23262200455ca2c21","width":400,"height":134}},"href":"https://mma.prnewswire.com/media/2431621/Satsuma_Pharmaceuticals_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are proud to announce the publication of this important impression and use data from our pivotal Phase 3 ASCEND study, which further reinforce the potential for STS101 to be a unique, well-tolerated treatment that has the potential to deliver rapid and enduring symptom relief for patients with acute migraine," said Ryoichi Nagata, President and CEO of Satsuma, M.D., Ph.D., FFPM. "We were particularly pleased to see that a vast majority of patients reported that STS101 was easy to use."","length":514,"tagName":"p"},{"type":"text","content":"In this study, most participants considered STS101 easy to use and indicated they would be l...